Thank you!

Your quote has been successfully submitted!

For products requiring additional information, our team will contact you within 1 business day

Failed

There was an error submitting your quote. Please try again.

Recombinant Human CLDN18.2/Claudin-18 A2 Protein (His Tag)– MSE Supplies LLC

Free Shipping on MSE PRO Online Orders of $500 or More! U.S. Orders Only * Offer Excludes Hazmat Shipments *

Menu

This product has been added to the cart.

Recombinant Human CLDN18.2/Claudin-18 A2 Protein (His Tag)

SKU: PKSH033470-50

  • £61100
  • Save £6800



Recombinant Human CLDN18.2/Claudin-18 A2 Protein (His Tag)

 

SKU # PKSH033470
Expression Host E.coli

 

 

Description

Synonyms CLDN18, Claudin-18
Species Human
Expression Host E.coli
Sequence Asp28-Leu76
Accession P56856-2
Calculated Molecular Weight 19.7 kDa
Observed Molecular Weight 18 kDa
Tag N-His
Bio-activity Not validated for activity
  

 

Properties

Purity > 95 % as determined by reducing SDS-PAGE.
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method.
Storage Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
Shipping This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < - 20°C.
Formulation Supplied as a 0.2 μm filtered solution of 25mM Tris-HCl, 25mM NaCl, 0.1% Triton X-100, 10% glycerol, 0.1mM GSH, 0.01mM GSSG, pH 8.0.
Reconstitution Not Applicable



Background

Claudin-18(CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.